A study has identified a role for the protein ENT1 in the onset and progression of metabolic liver disease, Infosalus reported on Tuesday, 20 October 2026. According to the outlet, the finding points to the protein as a possible therapeutic target against the condition.
Coverage of the research also appeared in IM Médico, which described ENT1 as a potential drug target for metabolic liver disease, and in MonPlaneta, which attributed the discoveries to the University of Barcelona (UB).
The reports do not include further details on the study's methods, its authors or where it was published. The available material also gives no information on the patient groups involved or on any experimental treatments tested.
Metabolic liver disease is the condition the coverage centres on. Beyond naming ENT1 as a factor in its appearance and development, the reports offer no figures on how common the disease is or how the protein might be acted on.
The identification of a possible target is an early step in research and does not by itself establish a treatment. Any clinical application would depend on further studies that are not described in the available reporting.
Watch for the full study and any follow-up work from the University of Barcelona team, which would clarify how ENT1 could be approached as a target and what stage the research has reached.